{"id":"NCT00861380","sponsor":"GlaxoSmithKline","briefTitle":"Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Against Invasive Disease","officialTitle":"Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Against Invasive Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-05-04","primaryCompletion":"2012-01-31","completion":"2013-10-05","firstPosted":"2009-03-13","resultsPosted":"2020-09-25","lastUpdate":"2020-12-17"},"enrollment":41188,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Infections, Streptococcal","Streptococcus Pneumoniae"],"interventions":[{"type":"BIOLOGICAL","name":"Pneumococcal conjugate vaccine GSK1024850A","otherNames":[]},{"type":"BIOLOGICAL","name":"GSK Biologicals' Engerix TM vaccine (Hepatitis B vaccine)","otherNames":[]},{"type":"BIOLOGICAL","name":"GSK Biologicals' Havrix TM vaccine (Hepatitis A vaccine)","otherNames":[]}],"arms":[{"label":"10Pn3+1-6W- 6M/043 Group","type":"EXPERIMENTAL"},{"label":"10Pn2+1-6W-6M/043 Group","type":"EXPERIMENTAL"},{"label":"Ctrl-6W-6M/043 Group","type":"ACTIVE_COMPARATOR"},{"label":"10Pn7-11M/043 Group","type":"EXPERIMENTAL"},{"label":"Ctrl7-11M/043 Group","type":"ACTIVE_COMPARATOR"},{"label":"10Pn12-18M/043 Group","type":"EXPERIMENTAL"},{"label":"Ctrl12-18M/043 Group","type":"ACTIVE_COMPARATOR"}],"summary":"The aim of this study is to assess the effectiveness of GSK Biologicals' pneumococcal conjugate vaccine (GSK1024850A), administered according to different vaccination schedules, against invasive disease caused by S. pneumoniae or H. influenzae as well as vaccine impact on the occurrence of hospital-diagnosed pneumonia cases, tympanostomy tube placement and outpatient antimicrobial prescriptions.\n\nThis study will also explore vaccine impact on occurrence of respiratory tract infections (RTIs), including acute otitis media (AOM) in a subset of children in Turku area.","primaryOutcome":{"measure":"Person Year Rate as Regards Subjects With Culture-confirmed IPD Due to Any of the 10 Pneumococcal Vaccine Serotypes. In Children Starting Vaccination Within 7 Months of Life and Assigned to a 3-dose Primary Vaccination Course","timeFrame":"Period of follow-up was any time after the administration of first vaccine dose till the end of the blinded invasive disease (ID) Follow-up period (The blinded ID Follow-up period lasted at least 30 months)","effectByArm":[{"arm":"10Pn3+1-6W-6M/043+053 Group","deltaMin":0,"sd":null},{"arm":"Ctrl-6W-6M/043+053 Group","deltaMin":0.564,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"6 Weeks","sex":"ALL","healthyVolunteers":true,"inclusionCount":2,"exclusionCount":5},"locations":{"siteCount":1,"countries":["Finland"]},"refs":{"pmids":["23158882","24287186","25127244","26284652","29503110","31122856","30145098","34986178","27125273"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":8427},"commonTop":[]}}